AbbVie is a global biopharmaceutical company whose corporate strategic venture capital arm, AbbVie Ventures, invests in novel, transformational therapeutics at discovery and pre-clinical stages. AbbVie Ventures focuses on early-stage opportunities in oncology, immunology, neuroscience, eye care, and aesthetics, investing the parent company's capital since 2009.
50% of their portfolio is in Biotech & Life Sciences. Deal activity increased 100% year-over-year (2 deals in the last 12 months). Their most common stage is series-a (45% of deals). Average disclosed round size is $56.7M (across 44 rounds with reported amounts).
Portfolio
44
Fund Size
—
Top Stage
Series A
Last 12 Mo
2
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
58 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| SSouffle Therapeutics | Series A | — | Aug 2026 |
 Third Arc Bio | Series A | $52M | Feb 2026 |
 ThirtyFiveBio Limited | Bridge | — | Apr 2025 |
 Accent Therapeutics | Series C | $75M | Jan 2024 |
| OOisin Biotechnologies | Series A | $15M | Jan 2024 |
 Mozart Therapeutics | Series A | $25M | Jun 2023 |
 Jnana Therapeutics | Series B | $50M | Jan 2023 |
 Nitrase Therapeutics | Series A | $45M | Nov 2021 |
| RRibon | Series B | $65M | Jul 2021 |
| SStemson Therapeutics | Series A | $15M | Jul 2021 |
| KKojin Therapeutics | Series A | $60M | Jun 2021 |
| CCapsida Biotherapeutics | Series A | $140M | Apr 2021 |
 Capsida | Series A | $50M | Apr 2021 |
| CCarisma Therapeutics, Inc. | Series B | — | Mar 2021 |
 Enthera | Series A | — | Jan 2021 |
| SStemson Therapeutics | Series A | $15M | Jan 2021 |
| EEnthera Pharmaceuticals | Series A | — | Dec 2020 |
 Palleon Pharmaceuticals | Series B | $100M | Sep 2020 |
| Accent Therapeutics | Series B | $63M | Apr 2020 |
 Quench Bio | Series A | $50M | Jan 2020 |
| Palleon Pharmaceuticals | Series B | $100M | Jan 2020 |
| Nitrase Therapeutics | Series A | $45M | Jan 2020 |
 Faze Medicines | Series A | $81M | Jan 2020 |
| NNitrome Biosciences | Series A | $38M | Jan 2020 |
 Prevail | Series B | $50M | Mar 2019 |
Page 1 of 3
Top Co-Investors
Sofinnova Partners13 shared
Alexandria Venture Investments12 shared
Pfizer Ventures11 shared
RA Capital Management10 shared
Surveyor Capital9 shared
MRL Ventures Fund9 shared
Omega Funds7 shared
Takeda Ventures, Inc.6 shared
Polaris Partners6 shared
Novartis Venture Fund6 shared
Eli Lilly and Company6 shared
SR One5 shared
SV Health Investors5 shared
M Ventures5 shared
Dementia Discovery Fund5 shared
Bristol Myers Squibb5 shared
Allergan5 shared
ARCH Venture Partners5 shared
TPG Biotech5 shared
Cormorant Asset Management4 shared
Last updated: 20 October 2026